Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

SOPHIA ANTIPOLIS, France, February 26 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced its financial results for full year 2008 and provided an overview of the development and pre-commercialization activities for naproxcinod, its lead investigational drug for the treatment of the signs and symptoms of osteoarthritis (OA).

Michele Garufi, Chief Executive Officer of NicOx, commented: "We believe NicOx has entered 2009 in its strongest strategic position to date. We intend to use the excellent platform that we have developed over the last several years to transform NicOx into a self-sustainable biopharmaceutical company. Central to our ambition is to maximize the strategic and economic value of naproxcinod by signing the most appropriate commercial deal for this unique new product. Our intention is to retain select commercialization rights to naproxcinod to enable the creation of our own sales and marketing operations. Therefore, in parallel with our on-going discussions with potential naproxcinod partners, we are accelerating our search for marketed or late-stage clinical products for in-licensing or acquisition to leverage our future commercial infrastructure. We are confident we will achieve these key near term milestones, which should position NicOx to deliver sustainable profitability in the mid-term."

    Key highlights 2008:

    - Successful completion of the phase 3 clinical program for naproxcinod
      in OA patients, with all three studies (301, 302 and 303) achieving
      highly statistically significant results on all three co-primary
      efficacy endpoints (the WOMAC(TM) pain and function subscales and
      patients' overall rating of disease status).

    - Positive results on naproxcinod's blood pressure profile from a
      prospectively designed statistical analysis of the pooled Office Blood
      Pressure Measurement (OBPM) data from the phase 3 pro
'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Pipette.com has ... to their comprehensive portfolio of Eppendorf products. , ... to purchase a Centrifuge 5424/5424 R and receive the ... either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... -- The Nano Science and Technology Institute (NSTI), today ... place May 3-7, 2009 at the George R. Brown Convention ... the largest and most prominent Nanotechnology event is expected to ... Bio technology executives, who will gather to promote advanced research ...
... Allscripts announced today that,Tully-Wihr Company, in conjunction ... to resell the web-based Allscripts MyWay(TM) Electronic,Health Record ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ... 1906, Tully-Wihr has been building forms management solutions,for ...
... BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced ... Dr. William P. Sheridan, Chief Medical Officer of BioCryst, will ... Healthcare Conference on Thursday, January 15, 2009 at 7:30 a.m. ... 2009 in San Francisco.A link to a live audio Web ...
Cached Biology Technology:NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 3NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 4Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 2Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 3Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 4Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 5BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 2BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 3
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... the tropical ocean coastlines, are far more important to ... the foul-smelling muddy forests may not have the scientific ... of researchers has noted that the woody coastline-dwelling plants ... carbon that is supplied to the global ocean from ...
... blubber falls below average levels may be at higher risk ... enough fat in their diets later on, according to a ... at Experimental Biology 2006. , The study found that harbor ... continued to gain weight and grow regardless of whether the ...
... transplantation performed in France spread around the world, plastic ... first full facial transplantation a reality. , In the ... surgeons demonstrated how to successfully complete a full facial ... the March issue of Plastic and Reconstructive Surgery® (PRS), ...
Cached Biology News:The critical importance of mangroves to ocean life 2Alaska seal pup diet may hold key to decline of population 2Alaska seal pup diet may hold key to decline of population 3Alaska seal pup diet may hold key to decline of population 4Plastic surgeons countdown first full facial transplantation 2